Gastrointestinal Radiofrequency Ablation Systems Market Segmentation:
Application (Surgical Oncology, Pain Management, Cardiology & Cardiac Rhythm Management, Cosmetology, Gynecology, and Others)
The surgical oncology segment is estimated to gain the largest market share of 32% by the end of 2035. The growth of the segment can be attributed to the increasing prevalence of cancer across the globe. RFA is frequently utilized in surgical oncology as a complement to surgery, especially for the treatment of colon, liver, and pancreatic cancer. For instance, RFA can be used to either reduce the size of tumors before surgical resection or to remove any malignant tissue that may be left over after surgery. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years. By 2040, there will be over 16 million cancer-related deaths globally and more than 29 million new instances of cancer annually.
End-User (Hospitals, Cancer Specialty Clinic, and Others)
The hospital segment is expected to hold the largest share of 52% during the forecast period. Hospitals are well-equipped to supply the specific tools and skilled medical personnel that treatments involving the digestive system normally call for. Besides this, if there are any difficulties, patients receiving gastrointestinal RFA operations may need to spend the night in the hospital for observation and monitoring. As a result, it is projected that this would generate a lot of prospects for the segment's growth in the years to come.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By End User |
|
